Is a possible benefit from longer-term docetaxel-based chemotherapy real?

A new paper in JAMA Oncology has suggested that longer docetaxel-based chemotherapy may be associated with longer survival for at least some men being treated for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Nuts to the Daily Telegraph … and nuts for most of our readers!

Finally, we may have the perfect paper that illustrates the critical difference between overall mortality rates and cancer-specific cancer rates among men with prostate cancer, and how affecting one may have no effect whatsoever on the other! … READ MORE …

Is overall survival a useful endpoint for evaluating therapies for intermediate-risk patients?

In a recent commentary, we looked at the utility of surrogate endpoints in evaluating therapies. … READ MORE …

Dose-escalated radiation therapy doesn’t impact survival within 10 years

Zaorsky et al. conducted a meta-analysis of 12 randomized clinical trials covering data on 6,884 patients treated with external beam radiation at various dose levels. … READ MORE …

Statin therapy lowers mortality rates among Danish prostate cancer patients

According to a media release and a presentation given at the European Association of Urology (EAU) in Europe this week, statin therapy has a small but significant impact on overall and prostate cancer-specific mortality rates. … READ MORE …

Site of prostate cancer metastasis and length of patient survival

There has long been information suggesting that exactly where prostate cancer metastasizes to (outside of the prostate itself) is really important to how long a patient might reasonably expect to survive once metastasis is evident. This is why patients with higher-risk disease get both a bone scan and a CT scan at diagnosis. … READS MORE –

Lowering risk of death from prostate cancer AND cardiovascular disease

Based on a specific case study, a new paper in Circulation by a group of clinicians at Vanderbilt University Medical Center describes their program designed to reduce risk of death from cardiovascular disease for prostate cancer patients on androgen deprivation therapy (ADT). … READ MORE …